StockData
DexCom Inc logo

DexCom Inc (DXCM) stock

DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3031% below fair value
$82.52+0.48 (+0.59%)

Close on Nov 18, 2026Market cap $30.78BP/E 32.5Yield –

DexCom revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

DexCom's revenue for the twelve months ending Sep 30, 2026 was $5.10B, up 13.0% year over year. For fiscal 2025 it was $4.66B, up 15.6% from the year before. Over ten years it grew 27.8% a year on average. The highest annual figure on record is $4.66B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.66B+15.6%
FY2024Dec 31, 2024$4.03B+11.3%
FY2023Dec 31, 2023$3.62B+24.5%
FY2022Dec 31, 2022$2.91B+18.8%
FY2021Dec 31, 2021$2.45B+27.1%
FY2020Dec 31, 2020$1.93B+30.5%
FY2019Dec 31, 2019$1.48B+43.1%
FY2018Dec 31, 2018$1.03B+43.6%
FY2017Dec 31, 2017$718.50M+25.3%
FY2016Dec 31, 2016$573.30M+42.6%
FY2015Dec 31, 2015$402.00M+55.1%
FY2014Dec 31, 2014$259.20M+62.0%
FY2013Dec 31, 2013$160.00M+60.2%
FY2012Dec 31, 2012$99.90M+30.9%
FY2011Dec 31, 2011$76.30M+57.0%
FY2010Dec 31, 2010$48.60M+63.7%
FY2009Dec 31, 2009$29.69M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.34B+11.2%
Q2 FY2026Jun 30, 2026$1.31B+13.1%
Q1 FY2026Mar 31, 2026$1.19B+15.0%
Q4 FY2025Dec 31, 2025$1.26B+13.1%
Q3 FY2025Sep 30, 2025$1.21B+21.6%
Q2 FY2025Jun 30, 2025$1.16B+15.2%
Q1 FY2025Mar 31, 2025$1.04B+12.5%
Q4 FY2024Dec 31, 2024$1.11B+7.6%
Q3 FY2024Sep 30, 2024$994.20M+2.0%
Q2 FY2024Jun 30, 2024$1.00B+15.3%
Q1 FY2024Mar 31, 2024$921.00M+24.2%
Q4 FY2023Dec 31, 2023$1.03B+26.9%
Q3 FY2023Sep 30, 2023$975.00M+26.7%
Q2 FY2023Jun 30, 2023$871.30M+25.2%
Q1 FY2023Mar 31, 2023$741.50M+17.9%
Q4 FY2022Dec 31, 2022$815.20M+16.8%
Q3 FY2022Sep 30, 2022$769.60M+18.4%
Q2 FY2022Jun 30, 2022$696.20M+17.0%
Q1 FY2022Mar 31, 2022$628.80M+24.5%
Q4 FY2021Dec 31, 2021$698.20M+22.7%
Q3 FY2021Sep 30, 2021$650.20M+29.8%
Q2 FY2021Jun 30, 2021$595.10M+31.7%
Q1 FY2021Mar 31, 2021$505.00M+24.7%
Q4 FY2020Dec 31, 2020$568.90M+22.9%
Q3 FY2020Sep 30, 2020$500.90M+26.4%
Q2 FY2020Jun 30, 2020$451.80M+34.3%
Q1 FY2020Mar 31, 2020$405.10M+44.4%
Q4 FY2019Dec 31, 2019$462.80M+36.9%
Q3 FY2019Sep 30, 2019$396.30M+48.6%
Q2 FY2019Jun 30, 2019$336.40M+38.7%
Q1 FY2019Mar 31, 2019$280.50M+52.1%
Q4 FY2018Dec 31, 2018$338.00M+52.9%
Q3 FY2018Sep 30, 2018$266.70M+44.5%
Q2 FY2018Jun 30, 2018$242.50M+42.1%
Q1 FY2018Mar 31, 2018$184.40M+29.6%
Q4 FY2017Dec 31, 2017$221.00M+29.1%
Q3 FY2017Sep 30, 2017$184.60M–
Q2 FY2017Jun 30, 2017$170.60M–
Q1 FY2017Mar 31, 2017$142.30M–
Q4 FY2016Dec 31, 2016$171.20M–

More DexCom figures

See a number that looks wrong?